Heat shock protein 90 (Hsp90) is a molecular chaperone that has emerged as an important target in cancer and several other diseases, such as neurodegenerative diseases, nerve injuries, inflammation, and infection. Discovery of novel agents that inhibit Hsp90 and have druglike properties is therefore a major focus in several academic and industrial laboratories. In this study, the authors describe the development and optimization in a 384-well format of a novel assay for the identification of Hsp90 inhibitors using fluorescence polarization, which measures competitive binding of red-shifted fluorescently labeled geldanamycin (GM-cy3B) to Hsp90 found in the NCI-N417 small-cell lung carcinoma cells. The authors demonstrate that GM-cy3B binds with high affinity and specificity to cellular Hsp90. The assay results in excellent signal-to-noise ratios (>10) and Z′ values (>0.75) at tracer concentrations greater than 4 nM and 1 µg/well of total NCI-N417 protein, indicating a robust assay. It also equilibrates after 5 h of incubation at room temperature and remains stable for up to 24 h. Furthermore, it is a simple mixand-read format that is cost-effective and uses only low amounts of fluorophore and cell lysates. A study using more than 15,000 compounds from the National Institutes of Health Molecular Libraries Screening Center Network was performed to validate its performance in a high-throughput screening format. (Journal of Biomolecular Screening 2007:915-924) 
INTRODUCTION
T HE MOLECULAR CHAPERONE Hsp90 is a protein with important roles in maintaining the malignant phenotype. [1] [2] [3] In this regard, it interacts with and stabilizes several client substrates, including kinases, hormone receptors, and transcription factors, that are directly involved in driving multistep malignancy and also with mutated oncogenic proteins that drive the transformed phenotype. Recent evidence suggests additional applications of Hsp90 inhibitors in neurodegenerative diseases, nerve injuries, inflammation, and infection. 2, 4 Accordingly, there has been increasing interest in developing novel inhibitors of this protein. 5 The biological activity of Hsp90 is regulated by an adenosine triphosphate/adenosine diphosphate binding pocket located at the N-terminal site of the chaperone; binding and release of these nucleotides determine the conformation state of the chaperone and drive its interaction with client proteins. 6 It is therefore of no surprise that the 1st identified Hsp90 inhibitors, such as the natural products geldanamycin (GM) and radicicol, target this regulatory pocket. 1, 5 Interest in Hsp90 as a therapeutic target in cancer has intensified after studies with GM and its derivative 17allylamino-17-demethoxygeldanamycin (17AAG) demonstrated that cancer cells are more susceptible than normal cells to Hsp90 inhibition. [1] [2] [3] 5 The appeal of Hsp90 as a clinical target has further increased following the observation that Hsp90 exists in tumors in a state of high affinity, hypothesized to confer the tumor selectivity observed for GM and 17AAG, whereas in normal tissues, Hsp90 is primarily in a latent, uncomplexed, low-affinity state. 7 These observations and the antitumor activity of 17AAG in preclinical models led several groups to initiate clinical trials of 17AAG in patients with advanced cancer. 8 The feasibility of Hsp90 as a therapeutic target has been further validated in these phase 1 and 2 trials of 17AAG and 17DMAG, in which activity as a single agent or in combination with chemotherapy has been observed. However, limitations in the use of ansamycins in the clinic have driven efforts toward the discovery of novel agents that interfere with the activity of the chaperone but have favorable druglike properties. 5, 8 Several assays have been developed to identify novel Hsp90 inhibitors in high-throughput screening (HTS) format. These include a filter binding assay that tested the competitive displacement of [ 3 H]17AAG binding to the N-terminal domain of human Hsp90α 9 ; a homogenous assay based on 2-dimensional fluorescence intensity distribution analysis of tetramethylrhodamine-labeled radicicol bound to Hsp90β 10 ; a colorimetric assay for inorganic phosphate based on the formation of a phosphomolybdate complex and subsequent reaction with malachite green, used to measure the ATPase activity of yeast Hsp90 11 ; an enzyme-coupled fluorescence-based assay measuring the ATPase activity of yeast Hsp90 12 ; a fluorescence polarization (FP) assay using a pyrazole-scaffold Hsp90 inhibitor and recombinant Hsp90β 13 ; and an FP assay for Hsp90 that probes the competitive binding of BODIPY-labeled GM to recombinant Hsp90α. 14 Although all are amenable for HTS, these assays determine the interaction of small molecules with recombinant Hsp90 protein, either yeast or human. Therefore, to measure a therapeutically significant state of Hsp90, we have developed an FP assay that uses human cancer cell lysates instead of recombinant protein. 15 It probes the interaction of small molecules with tumor-specific Hsp90 and may therefore lead to inhibitors not only selective for cancer cells but also specific for a particular malignancy.
Here, we present the optimization and validation of a 384well format Hsp90 FP assay that uses the small-cell lung carcinoma (SCLC) cell line NCI-N417 as a source of Hsp90 and the cy3B-labeled GM (GM-cy3B) as the FP ligand. We evaluate its performance in HTS format using more than 15,000 compounds from the National Institutes of Health (NIH) Molecular Libraries Screening Center Network (MLSCN).
MATERIALS AND METHODS
GM-cy3B and GM-FITC were synthesized as previously reported 16, 17 and were dissolved in DMSO to form 10-µM solutions. The assay buffer (HFB) contained 20 mM HEPES (K), pH 7.3, 50 mM KCl, 5 mM MgCl 2 , 20 mM Na 2 MoO 4 , and 0.01% NP40. Before each use, 0.1 mg/mL bovine gamma globulin (Panvera Corporation, Madison, WI) and 2 mM DTT (Fisher Biotech, Fair Lawn, NJ) were freshly added. The synthesis and characterization of PU-H71 are presented elsewhere. 18
Cell lysate preparation
The human cancer cell line NCI-N417 was obtained from the American Type Culture Collection (Manassas, VA). Cells were cultured in RPMI-1640 medium supplemented with 10 mM HEPES, 1 mM sodium pyruvate, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10% fetal bovine serum, 1% L-glutamine, 1% penicillin, and streptomycin. Cells were collected and frozen to rupture the membranes and then dissolved in binding buffer with added protease and phosphotase inhibitors to form the lysate. Lysates were stored at -20 °C before use. Total protein content was determined using the bicinchoninic acid assay kit (Pierce Biotechnology, Rockford, IL) according to the manufacturer's instructions.
Fluorescent ligand specificity determination
An aliquot of NCI-N417 protein lysate (14 µg) was depleted of Hsp90 protein by 3 rounds of consecutive incubations with anti-Hsp90 antibody (H90-10, a gift from David Toft, Mayo Clinic, Rochester, MN). A binding reaction containing the indicated amount of either protein lysate or Hsp90-depleted protein lysate and 5 µM GM-FITC in a buffer containing 20 mM HEPES, pH 7.3, 50 mM KCl, 5 mM MgCl 2 , 20 mM Na 2 MoO 4 , 0.01% NP40, 1 mM DTT, and protease inhibitors were incubated at 4 °C overnight. Samples were applied to a prerun, nondenaturing 7% polyacrylamide gel, and the gel was run in 50 mM Tris-HCl (pH 8.0) and 0.38 M glycine buffer at 100 V. The FITC signal was imaged with the CRI Maestro Fluorescence Imaging System (CRI Inc., Woburn, MA).
FP measurements
FP measurements were performed using black 384-well microplates (Corning Costar, Cambridge, MA) on an Analyst HT plate reader (Molecular Devices, Sunnyvale, CA). An integration time of 100 ms was used, and Z height was set at 2.15 mm (middle). The excitation polarization was set at static, and the emission polarization was set at dynamic. For GM-cy3B, an excitation filter at 545 nm and an emission filter at 610 to 675 nm were used with a dichroic mirror of 565 nm. All FP values were expressed in millipolarization (mP) units. The mP values were calculated using the equation mP = 1000 × [(I S -I SB ) -(I P -I PB )]/[(I S -I SB ) + (I P -I PB )], where I S is the parallel emission intensity measurement, I P is the perpendicular emission intensity sample measurement, and I SB and I SP are the corresponding measurements for background (buffer). Total fluorescence was determined as 2 × I P + I S . Specific binding was defined as the contribution to signal of bound ligand and was calculated as b × mP b = mP -f × mP f , where b and f are the fractions of bound and free tracer, respectively; mP is the recorded polarization value for a particular Hsp90 concentration; and mP f is the polarization value for free tracer. The assay window was calculated as the difference between the FP value recorded for the bound GM-cy3B and the FP value recorded for the free GM-cy3B (defined as mP -mP f ).
Assay development and optimization
The Hsp90 FP assay was carried out in black 384-well microplates in a total volume of 50 µL in each well. To determine the equilibrium binding of GM-cy3B and NCI-N417 cell lysate, increasing amounts of NCI-N417 cell lysate were incubated with 4, 6, or 8 nM of GM-cy3B. The plate was incubated at room temperature for different time periods, and the FP in mP was measured at room temperature with the Analyst HT reader (Molecular Devices). For assay performance, the signal-to-noise ratio (S:N) and the Z′ factor were calculated based on the following equations:
where SD b and SD f are the standard deviations for bound (b) (NCI-N417 cell lysate and GM-cy3B) and free (f) GM-cy3B (GM-cy3B only), respectively; µ b -µ f is the difference in mean signals for bound and free GM-cy3B; and Z′ factor = 1 -
where the Z′ factor reflects the quality of the assay itself without the intervention of test compounds. 19 All experimental data were analyzed using Microsoft Excel (Microsoft Corporation, Redmond, WA) and Prism 4.0 (Graphpad Software, San Diego, CA).
To test the assay stability, the binding experiment was measured after different incubation times at room temperature for up to 24 h. To test the effect of DMSO on the assay, different amounts of DMSO were added to the binding mixture containing GM-cy3B and the NCI-N417 cell lysate. FP was measured after a 5-h incubation at room temperature. All experimental data were analyzed using Microsoft Excel (Microsoft Corporation) and Prism 4.0 (Graphpad Software).
Competition FP assays
For the competition studies, FP assays were performed in a 384-well format. The Hsp90 inhibitor (PU-H71) dissolved in DMSO was added at several concentrations to the reaction buffer containing both 6 nM GM-cy3B and NCI-N417 cell lysate (1 µg/well or 2.5 µg/well) in a final volume of 50 µL. Free GM-cy3B (6 nM GM-cy3B) and bound GM-cy3B with NCI-N417 cell lysate (6 nM GM-cy3B and NCI-N417 cell lysate, 1 µg/well or 2.5 µg/well) were included as controls in each plate. Plates were incubated at room temperature, and polarization values were measured at several times (up to 22 h). The competitive efficiency of PU-H71 was expressed as a percentage of control. Percentage of inhibition was calculated as % of inhibition = 100 -((mPc -mPf)/(mPb -mPf)) × 100, where mPc is the recorded mP from compound wells, mPf is the average recorded mP from GM-cy3B-only wells, and mPb is the average recorded mP from wells containing both GM-cy3B and NCI-N417 lysate. EC 50 values were determined using a nonlinear regression analysis as implemented in Prism 4.0 (Graphpad Software).
High-throughput assay format
To evaluate the quality or suitability of the FP assay for HTS, the assay windows, the Z′ factor, and the S:N ratio were determined from assays performed in 30 microplates (384-well format). Each 384-well plate contained 8 wells of free GM-cy3B control and 8 wells of bound GM-cy3B control (5 nM of GM-cy3B with 1 µg/well NCI-N417 cell lysate). The mP value for each well was obtained and analyzed. The Z′ factor and the S:N ratios were calculated as described above.
Validation in HTS format
The assay reaction buffer containing 1 µg/well NCI-N417 cell lysate and 5 nM of GM-Cy3B in binding buffer was dispensed at 49.5 µL to 384-well black assay plates. The library compounds were added as 0.75 µL of 2 mM DMSO stocks to reach a final compound concentration of 30 µM and DMSO of 1.5% (v/v). Plates were incubated at room temperature overnight (15 h), and the FP signal in mP was measured at room temperature with an Analyst HT plate reader (Molecular Devices). Assay data were analyzed using CambridgeSoft. The activity cutoff was set as a percentage inhibition greater than 50%.
RESULTS AND DISCUSSION

Optimization of Hsp90 FP assay parameters
To translate this assay for use in a 384-well format, several parameters regarding the 1) fluorescent ligand and 2) its selectivity for the biological target need to be analyzed and optimized. In FP, the amount of polarization retained by a molecule depends on its Brownian rotation between absorption and emission. 20 A bound ligand will retain much of its polarization because the large molecular volume of the protein gives the complex a long rotational relaxation time. The free ligand, on the other hand, has a much smaller volume, so the rotational relaxation time is shorter than its fluorescence lifetime. The emitted radiation, therefore, has a polarization that is totally randomized.
Thus, in the particular case of the Hsp90 FP assay, when the relatively small, fast-tumbling, fluorescent-labeled Hsp90 inhibitor GM is excited with plane-polarized light, the emitted light is random with respect to the plane of polarization, resulting in a lower mP value. When this ligand is bound to Hsp90 (in this case, NCI-N417 cancer cell-specific Hsp90), the complex tumbles much slower, and the emitted light is polarized, resulting in a higher mP value. Thus, the change in mP reflects the interaction between the fluorescent-labeled GM and the Hsp90 protein present in the SCLC cell line NCI-N417. The mP value is proportional to the fractions of Hsp90-bound ligand, and the assay is very powerful in measuring real-time tumor Hsp90-inhibitor interactions in solution. Addition of agents that disrupt the Hsp90/GM complexes will result in a lowered mP signal that can be interpreted as a relative binding affinity (EC 50 ) of the agent for Hsp90.
Analysis and optimization of the Hsp90 fluorescent ligand.
Previously reported FP assays use fluorescein or BODIPY as fluorophores, 13, 14 thus limiting the applicability of these assays for HTS. 21 Autofluorescent compounds found in libraries of pure compounds or natural product extracts usually emit at the wavelength of these fluorophores and may result in false hits. The use of red-shifted dyes in labeling of the FP ligand may HTS Fluorescence Polarization Assay for Tumor-Specific Hsp90 eliminate this issue and, furthermore, reduce false positives resulted from light scattering caused by insoluble compounds. 22 Cy3B is a red-shifted dye that has been found to be particularly well suited for FP because of its increased fluorescence intensity, fluorescence lifetime of ∼2.9 ns, and stability of its signal in a variety of aqueous solvent conditions. 22 Concordantly, we introduce here a red-shifted geldanamycin (GM-cy3B) 16 to improve the suitability of the Hsp90 FP assay for HTS. To demonstrate a stable signal, the tracer's fluorescent quantum yield has to be significantly larger than that of the background (binding buffer) itself. As seen in Figure 1 , at greater than 4 nM GM-cy3B, the tracer's signal is more than 10 times larger than the background (Fig. 1A) and results in a constant tracer signal of approximately 60 to 70 mP (Fig. 1B) . In addition, at concentrations as low as 3 nM, the fluorescent signal of GM-cy3B does not experience interference from 30 µM quinacrine, a highly autofluorescent compound of the LOPAC™ library. 21 These data position GM-cy3B as especially suitable for the FP assay, suggesting that at the low concentrations of 4 to 10 nM, optimal for FP assays, it has the ability to reduce the number of false positives that may result from autofluorescent library compounds.
Analysis and optimization of GM-cy3B specificity for tumor Hsp90. To result in a valuable biological assay, the FP ligand has to bind specifically and with high affinity to the protein of interest. This is particularly important in the case of measuring ligand binding to a protein found in a mixture of a thousand others, such as in the case of this assay, in which cell lysates are used instead of recombinant protein. To determine the affinity of GM-cy3B for Hsp90 in these cells and to confirm that the ligand binds specifically to Hsp90 and not to other ATPases in the lysate protein mixture, we first evaluated binding curves that resulted from incubating cellular lysates with the ligand. As the amount of lysate increased, a greater fraction of fluorescent GM was bound, and polarization progressively increased to reach saturation ( Fig. 2A) . GM-cy3B bound well to Hsp90 in these lysates, resulting in an assay window of approximately 240 mP. The assay reached equilibrium by 5 h and remained stable for more than 24 h ( Fig. 2A) . The Hill and Scatchard plot analyses of the experiment demonstrated that at the low lysate amounts required to reach saturation, the interaction from other cellular material was precluded (Figs. 2C, D) . Analysis of the binding curve at equilibrium (longer than 5 h) suggested that at 5 µg total protein, more than 90% of GM-cy3B was Hsp90 bound (Fig. 2B) . Even at 1 µg total protein (∼50% bound), the assay window reached a robust value of 180 to 185 mP. In addition, a fluorescently labeled GM did not interact with the cellular mass in Hsp90-depleted cells ( Fig. 2E) . Collectively, these observations suggest that GM-cy3B is a specific highaffinity binder to Hsp90 in the SCLC cells.
Validation of the Hsp90 FP assay
To validate that the FP assay results correlate with a relevant biological parameter, we tested several known Hsp90 inhibitors whose affinity for the chaperone has been determined by alternative methods. We have previously validated the use of another fluorescently labeled GM, GM-BODIPY, with Hsp90 from cell lysates prepared from SKBr3 and MDA-MB-468, 2 breast cancer cell lines. 15, 18, 23 Competitive binding experiments measuring the displacement of GM-BODIPY/Hsp90 interaction in these cells by a large panel of our in-house-developed purine-scaffold Hsp90 inhibitors (approximately 60 derivatives) resulted in EC 50 values that correlated very well with the cellular activity of these compounds. Furthermore, the competitive FP assay had a wide detection range, being able to measure binding of high micromolar to low nanomolar Hsp90 inhibitors. Using this assay, the EC 50 values of 17AAG and GM for Hsp90 from several tumor cells were determined to be 14 ± 4 nM and 58.5 ± 20 nM in MCF-7 and 39.8 ± 1.3 nM and 38.3 ± 9.4 nM in SKBr3, respectively, which were values in good agreement with the antiproliferative activity of these compounds in these breast cancer cells. 15 Collectively, the data suggest that the fluorescently labeled GM tracer is specific for Hsp90 in cancer cells and that the assay measures a biologically relevant state of the chaperone. Recently, we have also validated the assay for the particular case of SCLC and demonstrated in a panel of 11 SCLC cell lines that relative binding affinities resulting from the Hsp90 FP assay correlate with the cytotoxic effect of Hsp90 inhibitors in these cells. 24 In particular, the competitive binding of 3 purine-scaffold agents, PU24FCl, 15 PU-H58, 23 and PU-H71, 18 to Hsp90 was analyzed in NCI-N417 cells. PU-H58 interacted approximately 10 times more avidly than PU24FCl with Hsp90, whereas PU-H71 was more potent than PU-H58 (EC 50 of 500 nM, 3000 nM, and 130 nM, respectively), and this translated to a similar ability in inhibiting the growth of these SCLC cells (IC 50 of 380 nM, 3500 nM, and 190 nM, respectively). PU-H71 binds to tumor Hsp90 with nanomolar affinity and exhibits biological activity in a large panel of cancer cells, with IC 50 s ranging from 35 to 300 nM. 17 When tested in the 384-well HTS FP assay format, the Hsp90-inhibitory effect of PU-H71 was stable, and EC 50 values recorded at assay equilibrium (5-22 h) were consistent with those recorded for cell inhibition (Fig. 3) , 18 both validating the Hsp90 FP assay and suggesting PU-H71 as an appropriate compound to use as positive control.
Analysis of the Hsp90 FP assay performance
To be amenable for HTS, the FP assay should exhibit little variation among plate-to-plate and well-to-well readings. Analysis across thirty 384-well plates demonstrated a constant assay window that, at 5 nM GM-cy3B and 1 µg/well lysate, reached approximately 180 mP (Fig. 4A) . To further evaluate the applicability of the 384-well FP assay for HTS, the assay performance parameters S:N and Z′ were determined (Fig. 4B) . 19, 25 For FP, a S:N value higher than 8 is recommended for reliable readings. The Z′ factor is a parameter for the quality of the assay itself without test compounds. Assays with a Z′ factor between 0.5 and 1.0 are considered to be reliable, robust, and suitable for HTS. As shown in Figure 4B , the Hsp90 FP assay resulted in excellent S:N (>20) ratios and Z′ values (>0.75) at tracer concentrations greater than 4 nM (Fig. 4B) .
Effect of DMSO on the Hsp90 FP assay performance
To assess the full applicability of the FP assays for HTS, it is necessary to test the effect of low concentrations of solvents, such as DMSO, that are used to solubilize test compounds prior to the addition of screening assays. The results on the effect of different concentrations of DMSO on the 384-well Hsp90 FP assay are shown in Figure 5 . The assay tolerated up to 8% (v/v) DMSO without significant effects on either the assay window or the assay performance parameters Z′ and S:N. Higher DMSO concentrations resulted in a slightly decreased window, although even at 10% to 16% (v/v) DMSO, the assay window was greater than 115 mP, and Z′ and S:N suggested an excellent assay (S:N >20, Z′ > 0.75; Fig. 5B ).
Analysis of the Hsp90 FP costs
Cost is another important issue to consider when setting up an HTS assay. The FP assay is cost-effective as it uses fluorophore in only low concentrations and small amounts of cell lysates and assay buffer. One milligram of GM-cy3B is sufficient to screen almost 4 mil compounds in the 384-well format. We also estimated that for screening the NIH compound library (approximately 100,000 compounds), one would require only 34 mL of NCI-N417 cell lysate (at a total protein concentration of 3.2 µg/µL) and 2.6 mL of GM-cy3B stock (10 µM). Thus, the HTS assay costs will mostly result from covering the plasticware and running the robotics.
Validation of the Hsp90 FP assay in HTS format
To validate the assay for HTS, we performed a test screen on a subset of 15,157 compounds from the NIH library ( Fig. 6) . Compounds were screened at a final concentration of 30 µM, whereas GM-cy3B and cell lysates were used at 5 nM and 1 µg/well, respectively. The assay resulted in 44 possible hits (hits were defined as compounds that decreased the assay window by more than 50%), which corresponds to a 0.29% hit rate. Analysis of fluorescence intensity signals read in wells containing these compounds suggested that 10 were likely to be false positives; the recorded fluorescence intensity signals were significantly elevated when compared with control. The results of this validation screen can be found at http://pubchem.ncbi.nlm.nih.gov/assay/ assay.cgi?aid=429. Representative hits from this screen are depicted in Figure 7A 
Validation of the Hsp90 FP assay hits
Compounds identified as hits from the initial screening were rescreened in the FP assay, and EC 50 measurements were conducted to establish hit validity. As seen in Figure 7B , both compounds ID 855681 (EC 50 = 2.3 µM) and ID 857148 (EC 50 = 9.1 µM) interfered in a dose-dependent manner with binding of GM-cy3B to Hsp90 in NCI-N417 cells.
Agents that inhibit the ATPase activity of Hsp90 alter the association of the chaperone with client proteins, resulting in their proteasomal degradation. [1] [2] [3] [4] [5] [6] The ubiquitous Raf serine/ threonine kinases are pivotal molecules within the Raf/mitogen extracellular kinase/extracellular signal-related kinase signaling pathway, which regulates cellular proliferation and survival. 28 Raf kinase isoforms (wild-type Raf-1 or the b-raf V600E oncogene), overactivated in a variety of solid tumor types, are tightly regulated by Hsp90. [1] [2] [3] [4] [5] [6] Previously, we have shown that an Hsp90 inhibitor induces the degradation of these kinases in a large panel 23 NCI-N417 cells were treated for 24 h with PU-H71 (1 µM), vehicle (DMSO), or compound ID 855681 (50 µM), and cells were lysed for Western blot analysis. β-actin was used as loading control. (D) Inhibition of Hsp90 in SKBr3 cells leads to the degradation of tyrosine kinase Her2. Cells were treated for 24 h with the indicated doses of Hsp90 inhibitors, and Her2 levels were determined as previously described. 18, 31 of cancer cells. 18 Concordantly, treatment of NCI-N417 cells with either PU-H71 or compound ID 855681 resulted in reduced cellular accumulation of Raf-1 (Fig. 7C ). Whereas in most tested cancer cells, an Hsp90 inhibitor has a cytostatic effect, 29 inhibition of Hsp90 in SCLC tumor cells results in spontaneous apoptosis that is effected through the intrinsic apoptotic pathway. 24 In agreement with these previous observations, both PU-H71 and compound ID 855681 induced significant caspase-3 cleavage in the NCI-N417 SCLC cells (Fig. 7C) .
Although Raf-1 seems to be an Hsp90 client in most transformed cells, others such as Her2 are transformation specific. Overexpression of the receptor tyrosine kinase Her2 in SKBr3 breast cancer cells leads to Akt activation, which in turn promotes cell survival. Hsp90 uniquely stabilizes Her2 via interaction with its kinase domain, and an Hsp90 inhibitor induces Her2 degradation by disrupting the Her2/Hsp90 association. 30, 31 Concordantly, both PU-H71 (EC 50 = 25 nM) and compound ID 855681 (EC 50 = 25 µM) led to a dose-dependent degradation of Her2 in these cells (Fig. 7D) .
In summary, we have developed, optimized, and validated an FP assay to identify in 384-well format novel inhibitors of tumor-specific Hsp90 ATPase activity. In addition to being a fast and cost-effective assay, the method is, to our knowledge, the only published Hsp90 HTS assay that measures inhibition of tumor Hsp90.
